@article{4193c7a87107441bb4d9b7cd20038df0,
title = "Metabolism-based therapies for epilepsy: new directions for future cures",
abstract = "Objective: Thousands of years after dietary therapy was proposed to treat seizures, how alterations in metabolism relates to epilepsy remains unclear, and metabolism-based therapies are not always effective. Methods: We consider the state of the science in metabolism-based therapies for epilepsy across the research lifecycle from basic to translational to clinical studies. Results: This analysis creates a conceptual framework for creative, rigorous, and transparent research to benefit people with epilepsy through the understanding and modification of metabolism. Interpretation: Despite intensive past efforts to evaluate metabolism-based therapies for epilepsy, distinct ways of framing a problem offer the chance to engage different mindsets and new (or newly applied) technologies. A comprehensive, creative, and inclusive problem-directed research agenda is needed, with a renewed and stringent adherence to rigor and transparency across all levels of investigation.",
author = "Mackenzie Cervenka and Pascual, {Juan M.} and Rho, {Jong M.} and Elizabeth Thiele and Gary Yellen and Vicky Whittemore and Hartman, {Adam L.}",
note = "Funding Information: The authors appreciate the editorial contributions of Alison F. Davis, Ph.D. Dr. Pascual was supported by US National Institutes of Health (grants NS094257 and NS102588). Dr. Rho was supported by Canadian Institutes of Health Research FRN‐162177 and NS104513. Dr. Yellen was supported by US National Institutes of Health (NS102586 and GM124038). Funding Information: The authors appreciate the editorial contributions of Alison F. Davis, Ph.D. Dr. Pascual was supported by US National Institutes of Health (grants NS094257 and NS102588). Dr. Rho was supported by Canadian Institutes of Health Research FRN-162177 and NS104513. Dr. Yellen was supported by US National Institutes of Health (NS102586 and GM124038). The authors gratefully acknowledge the active participation of the workshop panelists and participants. The authors appreciate the editorial contributions of Alison F. Davis, Ph.D. Dr. Pascual was supported by US National Institutes of Health (grants NS094257 and NS102588). Dr. Rho was supported by Canadian Institutes of Health Research FRN-162177 and NS104513. Dr. Yellen was supported by US National Institutes of Health (NS102586 and GM124038). This report does not represent the official view of the National Institute of Neurological Disorders and Stroke (NINDS), the National Institutes of Health (NIH), or any part of the US Federal Government. No official support or endorsement of this article by the NINDS or NIH is intended or should be inferred. Funding Information: The authors gratefully acknowledge the active participation of the workshop panelists and participants. The authors appreciate the editorial contributions of Alison F. Davis, Ph.D. Dr. Pascual was supported by US National Institutes of Health (grants NS094257 and NS102588). Dr. Rho was supported by Canadian Institutes of Health Research FRN‐162177 and NS104513. Dr. Yellen was supported by US National Institutes of Health (NS102586 and GM124038). This report does not represent the official view of the National Institute of Neurological Disorders and Stroke (NINDS), the National Institutes of Health (NIH), or any part of the US Federal Government. No official support or endorsement of this article by the NINDS or NIH is intended or should be inferred. Funding Information: Drs Pascual, Yellen, Thiele, Whittemore, and Hartman report no conflicts of interest. Dr Rho serves as a consultant for Aquestive Therapeutics, Cerecin Ltd., Biocodex, and Cypralis Ltd. Dr. Cervenka has received grants from Vitaflo International Ltd, honoraria from Nutricia and Vitaflo International Ltd, royalties from Demos Health/Springer Publishing Company, and consulting fees for Nutricia. Publisher Copyright: {\textcopyright} 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association. This article has been contributed to by US Government employees and their work is in the public domain in the USA",
year = "2021",
month = aug,
doi = "10.1002/acn3.51423",
language = "English (US)",
volume = "8",
pages = "1730--1737",
journal = "Annals of Clinical and Translational Neurology",
issn = "2328-9503",
publisher = "John Wiley and Sons Inc.",
number = "8",
}